Conference Day One: Tuesday, July 30
8:00 am Morning Break & Refreshments
8:30 am Chair’s Opening Remark
9:00 am Panel Discussion: Reflecting on a Year of Industry Advances: Key Insights from 2023 & Anticipating the Path Ahead in 2024
Synopsis
- Reviewing latest clinical updates and identifying key areas of growth in the past year
- Discussing the race to clinic and attracting investors to fund scale ups into the clinic
- Considering current gamma delta t therapies to drive solid tumor success
- What does 2024 look like for the field and where is it headed?
Clinical Advances in Liquid & Solid Tumors of Gamma Delta T Cell Therapies in 2024
9:45 am Clinical Data Update: DeltEx DRI Auto, DeltEx Allo, DeltEx nsCAR-T INB-300 & iPSC Derived Gamma-Delta T Cells
Synopsis
- DeltEx DRI Auto, is a genetically modified autologous gamma-delta T cell product candidate for the treatment of newly diagnosed GBM solid tumors
- DeltEx Allo, is an allogeneic product candidate initially developed for the treatment of patients with acute leukemia
- DeltEx nsCAR-T INB-300 is our DeltEx DRI non-signaling CAR (nsCAR) platform with several preclinical product candidates, including the INB-330 program targeting CD-33 for AML
10:15 am Antibody-Cell Conjugation Technology: Cutting-Edge Platform for Off-the-Shelf Cell Therapies
Synopsis
- Advantages of ACC technology in developing allogeneic cell therapies
- Mechanism of action of antibody-conjugated gamma delta T cells against tumors
- Preclinical evidence of ACC products against hematologic and solid malignancies
- Updates for IND application of ACC products
10:45 am Morning Refreshments & Speed Networking
Research & Translational Development
Fine-Tuning Mechanisms of Gamma Delta T Cells for Precise Solid Tumor Targeting
11:45 am Two Distinct Activation Methods Yield Clinical-Scale Expansion of γδ T Cells
Synopsis
- Expanding gamma delta (γδ) T cells – potential and challenges
- Protocol insights for two activation methods for clinical-scale expansion using TheraPEAK® T-VIVO® Cell Culture Medium:
- γδ T-cell expansion by zoledronic acid
- γδ T-cell expansion by anti-CD3/anti-CD28 co-stimulation
12:15 pm Harnessing the Power of the Innate Immunity to Fight Solid Tumor
Synopsis
- Developing off-the-shelf allogeneic healthy donor-derived γδ T cell therapy for solid tumor
- Polyclonal, natural composition of γδ T cell subsets, leveraging the non-redundant functions of diverse subsets
- Armed and engineered dual CAR targets tumor and immunesupporessive stroma in the TME to optimize anti-tumor potency
- Gene editing to overcome immune suppression in the solid tumor TME
Clinical Development & Product Optimization
Streamlining Clinical Trial Design for Improved Targeting of the TME
11:45 am Expanding the ImmTAX Platform to Gamma Delta T Cell Targets
Synopsis
- Introduction to the Immunocore ImmTAX platform and the first approved TCR bi-specific therapeutic.
- Establishment of a γδ TCR discovery platform
- Development of an affinity enhanced γδ TCR
12:15 pm Leveraging the Best Practice When Designing and Running a CAR-T Clinical Trial in Autoimmune and Oncology Indications
Synopsis
- Operational and regulatory environment considerations surrounding CAR T trials in autoimmune and oncology – regulatory, patient care and site perspectives; current treatment landscape
- Practicalities of running a CAR T trial in U.S vs globally.
- Best approaches and strategies to build internal clinical operations team and CRO partnerships
12:45 pm Lunch & Networking
Exploration of Engineering Strategies & their Influence on Cellular Attributes
1:45 pm Multimodal Immunotherapy Using Payload-Delivering Gamma Delta T cells
Synopsis
- Preclinical efficacy of OPS-gd T cells against solid tumours
- Modular engineering platform leveraging innate gd T cell biology
- Highly efficient lentiviral engineering of gd T cells
2:15 pm Establishment of an Allogeneic, Off-the-Shelf Platform for the Treatment of Solid Tumors
Synopsis
- Manufacturing of Deltacel, an allogenic, non-engineered, off-the shelf Gamma Delta T -cell therapy
- Combination of Deltacel with low-dose irradiation to improve treatment outcomes
- Interim results from Phase I clinical trial
- Using Deltacel as a platform for the creation of targeted immunotherapies
2:45 pm Precision Immunology and AI approaches for Donor Selection, Product Characterization and Patient Monitoring in Cell Therapy
Synopsis
- Super high resolution, scalable, cellular immune profiling
- Systems immunology and AI for optimal donor selection
- Characterization of cellular pharmacodynamics and host immune dynamics during treatment
3:00 pm Novel Approach for Genome Editing of gdT Cells Using CRISPR And AAV
Synopsis
- The importance of site-directed CAR gene insertion vs random insertion mediated by lentivectors
- Studying the effect of cytokines on providing optimal gene editing conditions
- The importance of Homology directed repair activation and chromosomal accessibility for efficient CAR generation
Model Techniques in Developing γδ T Cells at a Commercial Scale
1:45 pm Clinical Case Study: TC Biopharma’s Clinical Update
Synopsis
- Defining clear inclusion and exclusion criteria and previous treatments to ensure a homogeneous patient population
- Characterizing gamma delta T cells
- Implementing dose-escalation protocols, balancing safety, and efficacy in early phases of the clinical trial
2:15 pm Clinical Update – TCB008 and the Journey to ACHIEVE
Synopsis
- An overview of TC BioPharm’s clinical trial history that led to the development of our frozen off the shelf lead product
- Update of our current UK based clinical trail, ACHIEVE
- Outline of planned US based clinical trial and process development to enhance manufacturing capabilities and reducing costs
2:45 pm Round Table: Dose-Escalation Protocols in Gamma Delta T Cell Therapies for Optimal Safety and Efficacy
Synopsis
- Determining the highest dose level that does not cause unacceptable toxicity or adverse effects
- Assessing the therapeutic efficacy of Gamma Delta T cell therapies at each dose level, aiming to find a balance between safety and clinical effectiveness
- Defining clear clinical endpoints and criteria for dose escalation
More practical and highly interactive breakout roundtables where attendees can crowd-source solutions and share opinions around preassigned topic areas. This is a dedicated opportunity for you to voice your experience and identify unique solutions.
3:30 pm Afternoon Refreshments
Further Clinical Insights & Innovations in Gamma Delta T Therapeutics
4:00 pm Clinical Unpublished Data: Allogeneic Gamma Delta Immunotherapy for Acute Myeloid Leukemia
Synopsis
- Novel findings on VD2s and VD1s remain unpublished currently
- Research aims to evaluate the efficacy, safety, and potential benefits of gamma delta cell therapy in treating AcutAML
- Signifying the emergence of gamma delta cell therapy as a promising novel approach in AML management
4:30 pm GDT & CAR-T Preclinical Dual Targeting & Engineering Gamma Delta Cells
Synopsis
- Novel set of CARs that address challenges head on for both hematological malignancy and sold tumors
- Our solid tumor program utilizes a Dual CAR architecture to target multiple cancer antigens and more completely eradicate cancerous cells with a single engineered T cell product
- Establish an allogeneic dual targeting CAR that will consist of CSPG4 and CD70